Annexon, Inc.
ANNX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001528115
In the last 90 days, Annexon, Inc. insiders filed 1 open-market purchase and 0 sales; 216 institutions reported holding it in 13F filings for Q2 2026, worth $1.02B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Annexon, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $99.8K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$99.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Annexon, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Love Douglas | PRESIDENT AND CEO | 390,476 | Sep 25, 2026 | 2 |
| Blumenkranz Mark S. | Director | – | Aug 12, 2026 | 1 |
| Satter Muneer A | Director | 10,342,134Indirect | Jun 15, 2026 | 4 |
| Jones William A Jr | Director | – | Jun 15, 2026 | 1 |
| Waddill William D. | Director | – | Jun 15, 2026 | 1 |
| Choi Jung | Director | 33,000Indirect | Jun 15, 2026 | 2 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 184,807 | Jun 15, 2026 | 4 |
| Carson William H. | Director | 78,405 | Jun 15, 2026 | 8 |
| Cockroft Bettina M. | Director | – | Jun 15, 2026 | 1 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 170,700 | Mar 4, 2026 | 3 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | 123,582 | Mar 4, 2026 | 3 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 182,625 | Mar 4, 2026 | 3 |
| Artis Dean Richard | EVP & CHIEF SCIENTIFIC OFFICER | 180,093 | Mar 4, 2026 | 3 |
| Wiggans Thomas G | Director | – | Jun 9, 2025 | 0 |
| Bain Capital Life Sciences Fund, L.P. | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| BCIP Life Sciences Associates, LP | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| Bain Capital Life Sciences Partners, LP | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 5,701,926Indirect | May 30, 2023 | 0 |
| Mattheakis Larry | EVP & Chief Scientific Officer | 17,188 | Jul 13, 2022 | 0 |
| Keswani Sanjay Chandru | EVP & Chief Medical Officer | 12,500 | Feb 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 (view filing) | Jun 3 | 2 days | Carson William H.Director | PPurchase | +3.20K | $4.83 | +$15.5K | +50.0%9.60K after | 10b5-1 |
| May 3, 2024 (view filing) | May 1 | 2 days | Carson William H.Director | PPurchase | +3.20K | $4.68 | +$15.0K | +100.0%6.40K after | 10b5-1 |
| Apr 10, 2024 (view filing) | Apr 8 | 2 days | Carson William H.Director | PPurchase | +3.20K | $6.07 | +$19.4K | New position3.20K after | 10b5-1 |
| Feb 21, 2024 (view filing) | Feb 20 | 1 day | Yednock TedEVP & CHIEF INNOVATION OFFICER | SSale | −2.60K | $5.51 | −$14.3K | −3.5%72.5K after | |
| Feb 21, 2024 (view filing) | Feb 20 | 1 day | Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | SSale | −1.95K | $5.48 | −$10.7K | −2.2%85.6K after | |
| Feb 21, 2024 (view filing) | Feb 20 | 1 day | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | SSale | −2.59K | $5.53 | −$14.3K | −3.1%82.1K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | SSale | −1.35K | $5.53 | −$7.46K | −2.7%48.6K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Love DouglasPRESIDENT AND CEO | SSale | −5.78K | $5.54 | −$32.0K | −2.9%196.1K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Lew JenniferEVP & CHIEF FINANCIAL OFFICER | SSale | −1.81K | $5.54 | −$10.0K | −3.8%45.7K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Yednock TedEVP & CHIEF INNOVATION OFFICER | SSale | −1.81K | $5.54 | −$10.0K | −4.8%36.1K after | |
| Jan 23, 2024 (view filing) | Jul 11-Dec 27, 2023 | 196 days | Yednock TedEVP & Chief Innovation Officer | SSale | −22.1K | $4.49 | −$99.0K | −36.8%37.9K after | Amended2 lots10b5-1 |
| Jan 23, 2024 (view filing) | Jul 11, 2023 | 196 daysLate | Overdorf MichaelEVP & Chief Business Officer | SSale | −978 | $3.84 | −$3.76K | −2.1%45.8K after | |
| Jan 23, 2024 (view filing) | Jul 11, 2023 | 196 daysLate | Lew JenniferEVP & Chief Financial Officer | SSale | −1.06K | $3.84 | −$4.06K | −2.2%47.5K after | |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Satter Muneer ADirector, 10% Owner | PPurchase | +350.0K | $2.88 | +$1.01M | +5.0%7.41M after | |
| May 30, 2023 (view filing)9:54 PM ET | May 25 | 5 days | Bain Capital Life Sciences Fund, L.P. and 3 others10% Owner | PPurchase | +300.0K | $2.13 | +$639.7K | +5.6%5.70M after | |
| Feb 17, 2023 (view filing) | Feb 15 | 2 days | Love DouglasPresident & CEO | SSale | −6.57K | $5.87 | −$38.6K | −3.2%197.6K after | |
| Feb 15, 2023 (view filing) | Feb 13-14 | 2 days | Overdorf MichaelEVP & Chief Business Officer | SSale | −1.65K | $6.30 | −$10.4K | −5.6%27.8K after | 2 lots |
| Feb 15, 2023 (view filing) | Feb 13-14 | 2 days | Lew JenniferEVP & Chief Financial Officer | SSale | −1.91K | $6.31 | −$12.0K | −6.1%29.5K after | 2 lots |
| Feb 14, 2023 (view filing) | Feb 10 | 4 days | Satter Muneer ADirector, 10% Owner | PPurchase | +2.65M | $6.80 | +$18.0M | +60.0%7.06M after | |
| Jul 11, 2022 (view filing)8:42 PM ET | Jul 7 | 4 days | Satter Muneer ADirector | PPurchase | +2.45M | $3.84 | +$9.42M | +125.5%4.41M after | |
| Jul 11, 2022 (view filing)8:42 PM ET | Jul 7 | 4 days | Satter Muneer ADirector | PPurchase | +613.5K | $0.125 | +$76.7K | –613.5K after | Derivative |
| Apr 18, 2022 (view filing) | Apr 14 | 4 days | Love DouglasPresident & CEO | PPurchase | +60.0K | $2.45 | +$147.0K | +42.6%200.9K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Love DouglasPresident & CEO | SSale | −7.50K | $22.05 | −$165.4K | −100.0%0 after | |
| Sep 15, 2021 (view filing) | Sep 13 | 2 days | Yednock TedEVP & Chief Scientific Officer | SSale | −16.2K | $20.00 | −$323.8K | −100.0%0 after | |
| Sep 15, 2021 (view filing) | Sep 13 | 2 days | Lew JenniferEVP & Chief Financial Officer | SSale | −3.50K | $20.01 | −$70.0K | −63.6%2.00K after |